Buy Halidor pills 100 mg 50 pcs
  • Buy Halidor pills 100 mg 50 pcs

Halidor [Bencyclane]

Egis
1172 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$28.65
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Halidor - myotropic antispasmodic with a pronounced vasodilating action. The vasodilating action of the bentsklan is mainly due to its ability to block calcium channels, the antiserotonin action, and to a lesser extent to the blockade of sympathetic ganglia. Bentsyklan can cause dose-dependent suppression of Na + / K + -dependent ATPase and platelet aggregation and red blood cells, as well as increasing the elasticity of red blood cells. These effects are observed mainly in peripheral vessels, coronary arteries and cerebral vessels.
In addition, benziklan has an antispasmodic effect on the visceral muscles (gastrointestinal tract, urinary tract, respiratory organs).
The drug causes some increase in heart rate. Its weak tranquilizing effect is also known.

Indications

Vascular diseases:
- peripheral vascular diseases - Raynaud's disease, other diseases with acrocyanosis and vascular spasm, as well as chronic arterial obliterating diseases;
- cerebral vascular diseases: in the treatment of acute and chronic cerebral ischemia.
To eliminate spasm of internal organs:
- gastrointestinal diseases - gastroenteritis of various etiologies (especially infectious), infectious and inflammatory colitis, functional disorders of the colon, tenesmus, postoperative flatulence, cholecystitis, cholelithiasis, condition after cholecystectomy, dysmotility with dyskinesia of the sphincter of Oddi, gastric ulcer and duodenal guts (as part of combination therapy);
- urological syndromes: spasms and tenesmus of the bladder, concomitant therapy of urolithiasis (in combination with analgesics for renal colic);
Preparation for instrumental methods of research in urology (for solution for IV and IM injection).

Composition

1 tab .:
- Bentsiklana fumarat 100 mg
Excipients: potato starch, polyvinyl acetate, magnesium stearate, carbomer 934 P, sodium carboxymethyl starch (type A), anhydrous silicon colloidal dioxide, talc.

Bencyclane is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Halidor Egis Hungary pills
Halidor Egis Hungary solution

No customer reviews for the moment.

Write your review

Write your review

Halidor [Bencyclane]

Dosage and Administration

Vascular diseases:
Inside Halidor® administered 100 mg 3 times / day. within 2-3 months. The maximum daily dose for oral administration is 400 mg. The interval between courses is 2-3 months.
The drug can also be used in the form of intravenous infusion in a daily dose of 200 mg divided into 2 administrations. Before the infusion, 100 mg (4 ml) of the drug is diluted in 100-200 ml of isotonic sodium chloride solution and injected into / into the drip for 1 hour 2 times / day.
To eliminate spasm of internal organs:
Inside Halidor® prescribed in a dose of 100-200 mg once, but not more than 400 mg / day. For maintenance therapy prescribed 100 mg 3 times / day. for 3-4 weeks, then 100 mg 2 times / day. The duration of treatment is determined individually depending on the disappearance of the symptoms of the disease and, as a rule, does not exceed 1-2 months.
In acute cases, Halidor® is administered intravenously slowly at a dose of 100–200 mg (4–8 ml) or intramuscularly at a dose of 50 mg (2 ml). Before the on / in the introduction of the required amount of solution diluted with isotonic sodium chloride solution to 10-20 ml. The course of treatment is 2-3 weeks with the subsequent transfer of the patient, if necessary, to the intake of the drug Halidor®.

Adverse reactions

On the part of the digestive system: dry mouth, abdominal pain, feeling of fullness, nausea, vomiting, loss of appetite, diarrhea, increased serum hepatic transaminase activity.
From the side of the central nervous system: anxiety, dizziness, headache, gait disturbance, tremor, sleep disturbances, insomnia, memory disorders; rarely - transient confused state of consciousness, epileptiform seizures, hallucinations in elderly patients; in isolated cases - symptoms of focal CNS damage.
Since the cardiovascular system: sometimes - atrial and ventricular tachyarrhythmia (especially when combined with other proarrhythmic drugs).
Other: general malaise, weight gain, leukopenia, allergic reactions; rarely - thrombophlebitis with a / in the introduction.

Contraindications

- severe respiratory failure;
- renal failure severe;
- severe liver failure;
- decompensated heart failure;
- acute myocardial infarction;
- AV blockade;
- paroxysmal supraventricular or acute ventricular tachycardia;
- epilepsy and other forms of spasmophilia;
- recent hemorrhagic stroke;
- traumatic brain injury (during the last 12 months);
- pregnancy;
- lactation period (breastfeeding);
- children's and teenage age up to 18 years (insufficient experience of use);
- Hypersensitivity to the components of the drug Halidor.

Drug interactions

With the simultaneous use of Halidor ® enhances the depressant effect on the central nervous system means for anesthesia and sedatives.
With simultaneous use with sympathomimetics, the risk of developing tachycardia, atrial and ventricular tachyarrhythmias increases.
With the simultaneous use of Halidor and drugs that reduce the level of potassium in the blood (including diuretics, cardiac glycosides), and quinidine, the summation of proarrhythmic effects is possible.
With simultaneous use with drugs digitalis increases the risk of arrhythmias with an overdose of cardiac glycosides.
With the simultaneous use of Halidor with beta-blockers, it may be necessary to select the dose of beta-blocker because of the opposite of chronotropic effects (negative for beta-blockers and positive for bentsiklan).
With simultaneous use with calcium channel blockers and other antihypertensive drugs may increase their effect.
With the simultaneous use of Halidor with drugs that cause side effects in the form of spasmophilia, the summation of these effects is possible.
With simultaneous use with acetylsalicylic acid may increase inhibition of platelet aggregation.

Pregnancy and Lactation

Adequate and strictly controlled clinical studies on the use of the drug Halidor® during pregnancy and lactation have not been conducted. Therefore, the introduction of the drug in patients in the first trimester of pregnancy is not recommended.
If necessary, the use of the drug during lactation should decide on the termination of breastfeeding during treatment.
The data of preclinical studies did not reveal any embryotoxic or teratogenic effects.

Special instructions

With the simultaneous appointment of Halidor with drugs that cause hypokalemia, cardiac glycosides, with drugs that inhibit myocardial function, the daily dose of Halidor should not exceed 150-200 mg.
In case of parenteral administration, the injection sites should be changed, since The drug may cause damage to the vascular endothelium and thrombophlebitis.
Patients with severe cardiovascular or respiratory failure predisposed to collapse, as well as prostatic hypertrophy and urinary retention (the degree of delay increases with the relaxation of the bladder muscles) should be avoided from parenteral administration.
With long-term use of Halidor, systematic (at least 1 time in 2 months) laboratory tests of the rheological properties of blood are recommended.
Influence on ability to drive motor transport and control mechanisms
At the beginning of a course of treatment, patients should take special care when driving vehicles and other potentially hazardous activities.

Overdosage

Symptoms: an increase in heart rate, decreased blood pressure, collapse, impaired renal function, urinary incontinence, drowsiness, anxiety, in severe cases - epileptiform convulsive seizures. Significant overdose can cause tonic and clonic convulsions. Allergic reactions.
Treatment: symptomatic therapy. When taking a large number of pills should be a gastric lavage. Benzodiazepines are recommended for the treatment of seizures. The specific antidote is not known. There is no data on the possible elimination of a benziklan by dialysis.

  • Brand name: Halidor
  • Active ingredient: Bentsiklan
  • Dosage form: pills of white or grayish-white color, round, flat, with a facet, with an engraving "HALIDOR" on one side, with a faint characteristic odor.
  • Manufacturer: Egis
  • Country of Origin: Hungary

Studies and clinical trials of Bencyclane (Click to expand)

  1. Gas—liquid chromatographic evaluation of bencyclane in biological samples for pharmacokinetic and bioavailability investigations: comparison of two analytical methods
  2. EFFECT OF BENCYCLANE FUMARATE ON INTESTINAL ISCHAEMIA REPERFUSION INJURY
  3. Bencyclane as an anti-sickling agent
  4. Structure of N,N-dimethyl-3-{[1-(phenylmethyl)cycloheptyl]oxy}-1-propanamine fumarate (bencyclane hydrogen fumarate)
  5. The effect of bencyclane on the oxidative phosphorylation in isolated mitochondria of heart and liver
  6. Protection of oxidative phosphorylation by bencyclane against the damaging effect of mitochondrial swelling
  7. The inhibition of thrombocyte adhesion by bencyclane experimental and clinical results
  8. The effect of orally administered bencyclane on spontaneous platelet aggregation (PA) as a function of bencyclane concentration in coded samples
  9. The long-term tolerability of bencyclane (‘Fludilat’) in patients with peripheral occlusive disease: A 48-week prospective double-blind controlled study versus placebo
  10. Bencyclane overdose
  11. Radioimmunoassay of bencyclane in human serum.
  12. Studies on vasodilators. I. Synthesis and stereochemistry of the metabolites of bencyclane.
  13. Decomposition and Stabilization of drugs. XIX. Kinetic studies on the hydrolysis of bencyclane fumarate.
  14. Biopharmaceutical study of inclusion complexes. I. Pharmaceutical advantages of cyclodextrin complexes of bencyclane fumarate.
  15. Studies of cyclodextrin inclusion complexes. I. Complex between cyclodextrins and bencyclane in aqueous solution.
  16. Pial Arteriolar Reaction to Intravenous Administration of Bencyclane in the Cat

8 other products in the same category:

arrow_upward